Menu +

Corcept Closes Enrollment of Proof of Concept Clinical Study Evaluating Corlux® in Alzheimer's Disease

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it plans to close enrollment in its clinical study evaluating the safety and efficacy of CORLUX® to improve cognition in patients with mild to moderate Alzheimer's disease. Ongoing review of blinded safety data has not revealed any serious safety findings.

Patients in this trial were dosed with an acetylcholinesterase inhibitor, medications that are routinely prescribed for patients with Alzheimer's disease, and CORLUX or placebo. The study protocol prohibited the concomitant use of Namenda (memantine), a recently approved treatment for Alzheimer's disease which was commercialized after the Corcept trial was initiated. Because a majority of Alzheimer's disease patients are now treated with the combination of Namenda and an acetylcholinesterase inhibitor, enrollment in the Corcept study slowed significantly. The study has enrolled 80 patients to date. It was designed to enroll 160.

"Although this study is not powered to show statistically significant results with only 80 patients, we will analyze the data and see what we can learn", said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept. "We expect to report the results of this trial in the First Quarter of 2006."

ABOUT CORCEPT THERAPEUTICS INCORPORATED
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is currently in Phase III clinical trials for the treatment of the psychotic features of PMD. For additional information about the company, please visit www.corcept.com.

Statements made in this news release, other than statements of historical fact, are forward-looking statements, including, for example, statements relating to our clinical development programs and the expected results of our clinical trials. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. For example, there can be no assurances with respect to the commencement, cost, rate of spending, completion or success of clinical trials. These and other risk factors are set forth in the Company's SEC filings, all of which are available from our website (www.corcept.com) or from the SEC's website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.


CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
ir@corcept.com
www.corcept.com

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue